Organ Toxicity of Cancer Chemotherapy

[1]  Allen R. Chen,et al.  Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  Jeffrey McCullough,et al.  Dose of prophylactic platelet transfusions and prevention of hemorrhage. , 2010, The New England journal of medicine.

[3]  Allen R. Chen,et al.  Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  S. Pakakasama,et al.  Acute Pancreatitis in Children With Acute Lymphoblastic Leukemia After Chemotherapy , 2009, Journal of pediatric hematology/oncology.

[5]  H. Einsele,et al.  Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. , 2009, European journal of cancer.

[6]  K. Schmiegelow.  Advances in individual prediction of methotrexate toxicity: a review , 2009, British journal of haematology.

[7]  M. Earl.  Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia. , 2009, Clinical advances in hematology & oncology : H&O.

[8]  M. Paesmans,et al.  Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended? , 2009, Current opinion in oncology.

[9]  F. Roila,et al.  Management of febrile neutropenia: ESMO clinical recommendations. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  A. Kyritsis,et al.  Central and peripheral nervous system toxicity of common chemotherapeutic agents , 2009, Cancer Chemotherapy and Pharmacology.

[11]  H. Young,et al.  Role of proinflammatory cytokines IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice. , 2009, American journal of respiratory cell and molecular biology.

[12]  A. Shamseddine,et al.  Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. , 2009, Thrombosis research.

[13]  Y. Kwong,et al.  Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities , 2009, Annals of Hematology.

[14]  Youn-Jung Kim,et al.  Inflammation in methotrexate-induced pulmonary toxicity occurs via the p38 MAPK pathway. , 2009, Toxicology.

[15]  J. Esteve,et al.  Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. , 2009, Blood.

[16]  D. M. van der Heijde,et al.  Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research , 2008, Annals of the rheumatic diseases.

[17]  A. Czyż,et al.  Use of L-asparaginase in acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group. , 2008, Polskie Archiwum Medycyny Wewnetrznej.

[18]  L. Leibovici,et al.  Empirical antifungal therapy for patients with neutropenia and persistent fever: Systematic review and meta-analysis. , 2008, European journal of cancer.

[19]  M. Tashiro,et al.  Lung fibrosis 10 years after cessation of bleomycin therapy. , 2008, The Tohoku journal of experimental medicine.

[20]  C. Loprinzi,et al.  Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. , 2008, European journal of cancer.

[21]  R. Pollock,et al.  Challenges in Surgical Management of Abdominal Pain in the Neutropenic Cancer Patient , 2008, Annals of surgery.

[22]  G. Sudhandiran,et al.  Diallyl sulfide attenuates bleomycin-induced pulmonary fibrosis: critical role of iNOS, NF-kappaB, TNF-alpha and IL-1beta. , 2008, Life sciences.

[23]  W. Jędrzejczak,et al.  Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. Deray,et al.  Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care , 2008, Cancer Chemotherapy and Pharmacology.

[25]  P. Marik,et al.  Pulmonary complications of novel antineoplastic agents for solid tumors. , 2008, Chest.

[26]  David Schiff,et al.  Neurologic complications of chemotherapy agents , 2007, Current opinion in neurology.

[27]  M. Luppi,et al.  Cytarabine-related lung infiltrates on high resolution computerized tomography: a possible complication with benign outcome in leukemic patients , 2007, Haematologica.

[28]  M. Somerfield,et al.  American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  William M. Lee,et al.  Cancer chemotherapy I: hepatocellular injury. , 2007, Clinics in liver disease.

[30]  J. Perfect,et al.  Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  H. Izzedine,et al.  Gemcitabine-induced thrombotic microangiopathy: a systematic review. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[32]  N. Kearney,et al.  EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. , 2006, European journal of cancer.

[33]  P. Adamson,et al.  Understanding and managing methotrexate nephrotoxicity. , 2006, The oncologist.

[34]  S. Kudoh,et al.  Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate , 2006, Leukemia.

[35]  S. Belknap,et al.  Clinical features and correlates of gemcitabine‐associated lung injury , 2006, Cancer.

[36]  J. Baars,et al.  Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. , 2006, Blood.

[37]  J. Fleck,et al.  Bleomycin lung toxicity: who are the patients with increased risk? , 2005, Pulmonary pharmacology & therapeutics.

[38]  A. Armaganidis,et al.  Cytarabine-induced lung injury: case report. , 2005, Anti-cancer drugs.

[39]  M. Yaman,et al.  Delayed onset bleomycin-induced pneumonitis. , 2005, Urology.

[40]  F. Shepherd,et al.  Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  L. Napolitano,et al.  Neutropenic Enterocolitis in Adults: Case Series and Review of the Literature , 2005, Digestive Diseases and Sciences.

[42]  A. Craft,et al.  High‐dose methotrexate‐induced nephrotoxicity in patients with osteosarcoma , 2004, Cancer.

[43]  É. Azoulay,et al.  Improved survival of critically ill cancer patients with septic shock , 2003, Intensive Care Medicine.

[44]  A. Hauschild,et al.  Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T‐cell lymphoma , 2003, Cancer.

[45]  T. Barbui,et al.  Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). , 2003, Blood.

[46]  J. Hainsworth,et al.  Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  L. Brochard,et al.  Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis , 2003, Critical care medicine.

[48]  M. J. van den Bent,et al.  Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients , 2003, British Journal of Cancer.

[49]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[50]  G. Hortobagyi,et al.  A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  É. Azoulay,et al.  Impact of neutropenia duration on short-term mortality in neutropenic critically ill cancer patients , 2002, Intensive Care Medicine.

[52]  Hermann Brenner,et al.  Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis , 2002, The Lancet.

[53]  J. Jamart,et al.  Prognosis of hematologic malignancies does not predict intensive care unit mortality , 2002, Critical care medicine.

[54]  S. Woolf,et al.  Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. , 2002, Blood.

[55]  Sylvie Chevret,et al.  Compliance with triage to intensive care recommendations , 2001, Critical care medicine.

[56]  J. Bernaudin,et al.  Spectrum of CD4 to CD8 T-cell ratios in lymphocytic alveolitis associated with methotrexate-induced pneumonitis. , 2001, American journal of respiratory and critical care medicine.

[57]  E. Perez,et al.  Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects. , 2001, Seminars in oncology.

[58]  S. Sleijfer.  Bleomycin-induced pneumonitis. , 2001, Chest.

[59]  Willem Boogerd,et al.  Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure , 2001, Cancer Chemotherapy and Pharmacology.

[60]  S. Chevret,et al.  Improved survival in cancer patients requiring mechanical ventilatory support: Impact of noninvasive mechanical ventilatory support , 2001, Critical care medicine.

[61]  D. Gruson,et al.  Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. , 2001, The New England journal of medicine.

[62]  G. Leleu,et al.  Predictors of short-term mortality in critically ill patients with solid malignancies , 2000, Intensive Care Medicine.

[63]  P C Goodman,et al.  Pulmonary drug toxicity: radiologic and pathologic manifestations. , 2000, Radiographics : a review publication of the Radiological Society of North America, Inc.

[64]  O. Casasnovas,et al.  Dobutamine stress echocardiography identifies anthracycline cardiotoxicity. , 2000, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[65]  A. Saraste,et al.  Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. , 2000, Cancer research.

[66]  M. Nahata,et al.  Cardiotoxicity of Chemotherapeutic Agents , 2000 .

[67]  J. Wojtacki,et al.  Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention--review of the literature. , 2000, Medical science monitor : international medical journal of experimental and clinical research.

[68]  T. Colby,et al.  Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. , 2000, The European respiratory journal.

[69]  J. Kress,et al.  Outcomes of critically ill cancer patients in a university hospital setting. , 1999, American journal of respiratory and critical care medicine.

[70]  W. Gradishar,et al.  Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  P. Singal,et al.  Doxorubicin-induced cardiomyopathy. , 1998, The New England journal of medicine.

[72]  G. Rustin,et al.  High-dose therapy including carboplatin adjusted for renal function in patients with relapsed or refractory germ cell tumour: outcome and prognostic factors. , 1998, British Journal of Cancer.

[73]  W. Siegert,et al.  Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome , 1997, Bone Marrow Transplantation.

[74]  N. West,et al.  Prevention and Treatment of Hemorrhagic Cystitis , 1997, Pharmacotherapy.

[75]  J. Hainsworth,et al.  Paclitaxel via 1-hour infusion: clinical experience. , 1996, Seminars in oncology.

[76]  T. Berghmans.  Hyponatremia related to medical anticancer treatment , 1996, Supportive Care in Cancer.

[77]  T. Schwinghammer,et al.  Efficacy of Mesna for Prevention of Hemorrhagic Cystitis After High-Dose Cyclophosphamide Therapy , 1995, The Annals of pharmacotherapy.

[78]  Craig Lewis.  A Review of the Use of Chemoprotectants in Cancer Chemotherapy , 1994, Drug safety.

[79]  Robert M. Nelson,et al.  Consensus Statement on the Triage of Critically III Patients , 1994 .

[80]  R. Nygaard,et al.  Evaluation of serious adverse events in patients treated with protocols including methotrexate infusions. , 1994, Pediatric hematology and oncology.

[81]  J. Beijnen,et al.  The analysis of ifosfamide and its metabolites (review). , 1993, Anticancer research.

[82]  D. Schuster.  Everything that should be done--not everything that can be done. , 1992, The American review of respiratory disease.

[83]  H. Yokozaki,et al.  Anthracycline induced myocardial damage. An analysis of 16 autopsy cases. , 1986, Pathology, research and practice.

[84]  U. Baandrup,et al.  Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease. , 1986, British heart journal.

[85]  G. Bodey,et al.  Fever and infection in leukemic patients. A study of 494 consecutive patients , 1978, Cancer.

[86]  R. Chesney,et al.  Electrolyte and acid-base disturbances in the management of leukemia. , 1977, Blood.

[87]  F. Oski,et al.  Syndrome of recurrent increased secretion of antidiuretic hormone following multiple doses of vincristine. , 1975, Blood.

[88]  A. Moses,et al.  Drug-induced dilutional hyponatremia. , 1974, The New England journal of medicine.

[89]  Jan J. Heimans,et al.  Neurotoxic Complications of Chemotherapy in Patients with Cancer , 2012, Drugs.

[90]  M. Marques,et al.  Is therapeutic plasma exchange indicated for patients with gemcitabine‐induced hemolytic uremic syndrome? , 2009, Journal of clinical apheresis.

[91]  C. Burgaleta,et al.  Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugs , 2008 .

[92]  A. Elias,et al.  High-dose ifosfamide, carboplatin, and etoposide pharmacokinetics: correlation of plasma drug levels with renal toxicity , 2004, Cancer Chemotherapy and Pharmacology.

[93]  G. Remuzzi,et al.  Drug-Induced Thrombotic Microangiopathy , 2001, Drug safety.

[94]  P. Kintzel.  Anticancer Drug—Induced Kidney Disorders , 2001, Drug safety.

[95]  A. Egol.  Guidelines for intensive care unit admission, discharge, and triage , 1999 .

[96]  G. Carlon.  Admitting cancer patients to the intensive care unit. , 1988, Critical care clinics.